Literature DB >> 19114672

A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.

George Dimopoulos1, Aristea Velegraki, Matthew E Falagas.   

Abstract

This study retrospectively reviews the susceptibility of 135 baseline ICU candidemia isolates (from 1997 to 2007) to nine antifungals as determined by the AFST-EUCAST microdilution method and identifies the most frequent causative agents of confirmed point-source candidemia outbreaks in local intensive care units. A minority of common and rare Candida species displayed decreased susceptibility to all antifungals.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19114672      PMCID： PMC2650580          DOI： 10.1128/AAC.01368-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory.

Authors:  Christopher J Linton; Andrew M Borman; Grace Cheung; Ann D Holmes; Adrien Szekely; Michael D Palmer; Paul D Bridge; Colin K Campbell; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

2.  EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-01-11       Impact factor: 8.067

3.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

4.  Nosocomial infections in combined medical-surgical intensive care units in the United States.

Authors:  M J Richards; J R Edwards; D H Culver; R P Gaynes
Journal:  Infect Control Hosp Epidemiol       Date:  2000-08       Impact factor: 3.254

5.  Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).

Authors:  Juan Luis Rodriguez-Tudela; J Peter Donnelly; Michael A Pfaller; Erja Chryssantou; Peter Warn; David W Denning; Ana Espinel-Ingroff; Francesco Barchiesi; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

6.  Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Cornelia Lass-Flörl; Astrid Mayr; Susanne Perkhofer; Guido Hinterberger; Johann Hausdorfer; Cornelia Speth; Manfred Fille
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

Review 7.  Management of candidiasis in the intensive care unit.

Authors:  Silke Schelenz
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

8.  Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.

Authors:  George Dimopoulos; Fotinie Ntziora; George Rachiotis; Apostolos Armaganidis; Matthew E Falagas
Journal:  Anesth Analg       Date:  2008-02       Impact factor: 5.108

9.  Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study.

Authors:  C León; F Alvarez-Lerma; S Ruiz-Santana; M A León; J Nolla; R Jordá; P Saavedra; M Palomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-29       Impact factor: 3.267

10.  Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.

Authors:  Nikolaos Lolis; Dimitrios Veldekis; Hellen Moraitou; Sofia Kanavaki; Aristea Velegraki; Charis Triandafyllidis; Chronis Tasioudis; Angellos Pefanis; Ioannis Pneumatikos
Journal:  Crit Care       Date:  2008-04-09       Impact factor: 9.097
View more
  12 in total

1.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital.

Authors:  L X Bonfietti; M W Szeszs; M R Chang; M A Martins; S R B S Pukinskas; M O Nunes; G H Pereira; A M M Paniago; S U Purisco; M S C Melhem
Journal:  Mycopathologia       Date:  2012-07-21       Impact factor: 2.574

3.  Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.

Authors:  David Ferreira; Frederic Grenouillet; Gilles Blasco; Emmanuel Samain; Thierry Hénon; Alain Dussaucy; Laurence Millon; Mariette Mercier; Sebastien Pili-Floury
Journal:  Intensive Care Med       Date:  2015-04-18       Impact factor: 17.440

4.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099

5.  Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.

Authors:  Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

6.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

7.  Comparison of the epidemiology, risk factors, outcome and degree of organ failures of patients with candidemia acquired before or during ICU treatment.

Authors:  Pekka Ylipalosaari; Tero I Ala-Kokko; Juha Karhu; Markku Koskela; Jouko Laurila; Pasi Ohtonen; Hannu Syrjälä
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

Review 8.  Current perspective on emergence, diagnosis and drug resistance in Candida auris.

Authors:  Smita Sarma; Shalini Upadhyay
Journal:  Infect Drug Resist       Date:  2017-06-07       Impact factor: 4.003

Review 9.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

10.  Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant Candida parapsilosis Isolates in the Galleria mellonella Model.

Authors:  Ulrike Binder; Amir Arastehfar; Lisa Schnegg; Caroline Hörtnagl; Suleyha Hilmioğlu-Polat; David S Perlin; Cornelia Lass-Flörl
Journal:  J Fungi (Basel)       Date:  2020-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.